1. Innovations and Issues in Mantle Cell Lymphoma

2. Program Goals

3. MCL

4. MIPI

5. Less- vs More-Intensive Initial Treatments

6. Watch and Wait

7. MCL Treatment by Patient Type

8. StiL: BR vs R-CHOP

9. R-FC vs R-CHOP → Maintenance IFN-alpha or Rituximab

10. Novel Agents

11. R-CHOP vs VR-CAP

12. Nontransplant Options Based on Randomized Data

13. ASCT Studies

14. Approach Comparison by Patient Characteristics

15. ASCT vs IFN-alpha European MCL Network

16. Outcomes According to MIPI Risk: Pooled Analysis of European MCL Network Trials

17. Other Approaches to MCL

18. PINNACLE: Bortezomib in Relapsed/Refractory MCL (Single-Arm Phase 2 Trial)

19. MCL-001 (EMERGE): Lenalidomide in Relapsed/Refractory MCL (Single-Arm Phase 2 Trial)

20. Upfront Lenalidomide + Rituximab

21. E1411: Phase 2 Intergroup Trial of Initial MCL Therapy in Older Patients

22. Phase 2: Ibrutinib in Relapsed/Refractory MCL

23. TRIANGLE Study: European MCL Network

24. Venetoclax (ABT-199)—Phase 1

25. Conclusions